Lassen Therapeutics reels in $85M Series B for PhII testing in thyroid eye disease

Kyle LaHucik

Senior Reporter

Lassen Therapeutics closed an oversubscribed $85 million Series B on Tuesday morning as the San Diego biotech brings its treatment candidate for thyroid eye disease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lassen Therapeutics reels in $85M Series B for PhII testing in thyroid eye disease

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership

Drugmakers exploit cancer’s ‘lethalities’ to make next class of targeted therapies, with first results for ...

Exclusive: After FDA firings, drug reviewers are asked to volunteer for administrative work

The inside story of how SalioGen, a startup trying to wrangle ‘jumping genes’ to make medicines, fell apart

Feng Zhang’s protein nanoparticle startup Aera Therapeutics turns to lipid nanoparticles to jumpstart its pipeline

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Lassen Ther­a­peu­tics reels in $85M Se­ries B for PhII test­ing in thy­roid eye dis­ease

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Lassen Therapeutics reels in $85M Series B for PhII testing in thyroid eye disease